$9M Shaved From Novartis Jaw Injury Award By NY Judge

Law360, New York (October 11, 2013, 6:37 PM EDT) -- A New York judge on Wednesday denied Novartis Pharmaceuticals Corp.’s bid for a mistrial declaration in litigation over jaw deterioration injuries purportedly linked to bone drug Zometa, but slashed a $10 million punitive damage award to just less than $1 million.

U.S. District Court Judge Arthur Spatt rejected Novartis's argument that a juror had improperly relied on external information in reaching the damage award in a November 2012 plaintiff's verdict by consulting the dictionary for a definition of the word “wanton,” saying those allegations are based on...
To view the full article, register now.



Case Information

Case Title

Davids et al v. Novartis Pharmaceuticals Corporation

Case Number



New York Eastern

Nature of Suit

Personal Inj. Prod. Liability


Arthur D. Spatt

Date Filed

January 31, 2006

Law Firms


Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.